根治性前列腺切除术后放疗时机的长期结局:RADICALS-RT试验(NCT00541047)
RADICALS-RT是一项随机对照试验,纳入1396例具有复发危险因素的前列腺癌患者,比较辅助放疗与观察策略下挽救性放疗的疗效与安全性。中位随访7.8年,10年无远处转移生存率辅助放疗组93% vs 挽救性放疗组90%(HR=0.68,95%CI 0.43-1.07,P=0.095),总生存无改善(HR=0.980,95%CI 0.667-1.440,P=0.917)。辅助放疗增加泌尿和肠道并发症。
要点
- 辅助放疗组10年无远处转移生存率93%,挽救性放疗组90%,差异未达统计学显著(HR=0.68,P=0.095)。
- 总生存无改善(HR=0.980,95%CI 0.667-1.440,P=0.917)。
- 辅助放疗组随机化后1年泌尿和粪便失禁更差(P=0.001),粪便失禁10年后仍显著(P=0.017)。
核心结论
- RADICALS-RT长期结果显示,根治性前列腺切除术后辅助放疗增加泌尿和肠道并发症风险,但未显著改善疾病控制。
- 对PSA失败采取观察策略并予以挽救性放疗应作为根治性前列腺切除术后的当前标准。
研究设计与样本
- RADICALS-RT为随机对照试验,纳入具有≥1项复发危险因素(pT3/4、Gleason评分7-10、切缘阳性、术前PSA≥10 ng/ml)的前列腺癌根治术后患者。
- 患者按1:1随机分配至辅助放疗组(Adjuvant-RT)或观察策略下PSA失败后挽救性放疗组(Salvage-RT),PSA失败定义为PSA≥0.1 ng/ml或连续三次升高。
- 分层因素为Gleason评分、切缘状态、计划放疗方案(52.5 Gy/20次或66 Gy/33次)和治疗中心。
- 主要终点为无远处转移生存(FFDM),设计把握度为80%,检测10年FFDM从挽救性放疗组(对照)90%提高至辅助放疗组95%。
- 2007年10月至2016年12月,来自英国、丹麦、加拿大和爱尔兰的1396例参与者被随机分组:挽救性放疗组699例,辅助放疗组697例。
主要发现
- 辅助放疗组93%(649/697)在随机化后6个月内接受放疗;挽救性放疗组39%(270/699)在随访期间接受放疗。
- 中位随访7.8年,共80例远处转移事件,10年FFDM辅助放疗组93% vs 挽救性放疗组90%(HR=0.68,95%CI 0.43-1.07,P=0.095)。
- 共109例死亡,其中17例死于前列腺癌;总生存无改善(HR=0.980,95%CI 0.667-1.440,P=0.917)。
- 辅助放疗组随机化后1年报告更差的泌尿和粪便失禁(P=0.001);粪便失禁10年后仍显著(P=0.017)。
临床怎么用
- 对根治性前列腺切除术后具有复发危险因素的患者,观察策略下PSA失败后行挽救性放疗应作为当前标准。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for prostate-specific antigen (PSA) failure. PATIENTS AND METHODS: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, preoperative PSA≥10 ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT ('Adjuvant-RT') or an observation policy with salvage RT for PSA failure ('Salvage-RT') defined as PSA≥0.1 ng/ml or three consecutive rises. Stratification factors were Gleason score, margin status, planned RT schedule (52.5 Gy/20 fractions or 66 Gy/33 fractions) and treatment centre. The primary outcome measure was freedom-from-distant-metastasis (FFDM), designed with 80% power to detect an improvement from 90% with Salvage-RT (control) to 95% at 10 years with Adjuvant-RT. Secondary outcome measures were biochemical progression-free survival, freedom from non-protocol hormone therapy, safety and patient-reported outcomes. Standard survival analysis methods were used; hazard ratio (HR)<1 favours Adjuvant-RT. RESULTS: Between October 2007 and December 2016, 1396 participants from UK, Denmark, Canada and Ireland were randomised: 699 Salvage-RT, 697 Adjuvant-RT. Allocated groups were balanced with a median age of 65 years. Ninety-three percent (649/697) Adjuvant-RT reported RT within 6 months after randomisation; 39% (270/699) Salvage-RT reported RT during follow-up. Median follow-up was 7.8 years. With 80 distant metastasis events, 10-year FFDM was 93% for Adjuvant-RT and 90% for Salvage-RT: HR=0.68 [95% confidence interval (CI) 0.43-1.07, P=0.095]. Of 109 deaths, 17 were due to prostate cancer. Overall survival was not improved (HR=0.980, 95% CI 0.667-1.440, P=0.917). Adjuvant-RT reported worse urinary and faecal incontinence 1 year after randomisation (P=0.001); faecal incontinence remained significant after 10 years (P=0.017). CONCLUSION: Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy. TRIAL IDENTIFICATION: RADICALS, RADICALS-RT, ISRCTN40814031, NCT00541047.
引用
- Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol. 2024. PMID: 38583574. doi:10.1016/j.annonc.2024.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。